Gangnam Severance Hospital
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1983-04-01
- Employees
- -
- Market Cap
- -
Clinical Trials
135
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (108 trials with phase data)• Click on a phase to view related trials
Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score
- Conditions
- Breast CancerTumor Grade
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 4000
- Registration Number
- NCT07093775
Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis, Multicenter, Phase 4 Study
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 77
- Registration Number
- NCT07025460
- Locations
- 🇰🇷
Institutional Review Board, Gangnam Severance Hospitial Yonsei University College of Medicine, Seoul, Korea, Republic of
Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC
- Conditions
- Triple-Negative Breast Neoplasm
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT07011823
Comparison of Full Robotic Instrumentation and Assistant-Controlled Laparoscopic Instrumentation in Robotic Distal Gastrectomy
- Conditions
- Gastric Cancer
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06841484
- Locations
- 🇰🇷
GangnamSeveranceHospital, Seoul, Korea, Republic of
Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic Gastrectomy
- Conditions
- Gastric Cancer
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 134
- Registration Number
- NCT06839716
- Locations
- 🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 27
- Next
News
Ovarian Function Suppression Enhances Survival in Select HER2-Positive Breast Cancer
• Exploratory analysis of the HERA trial reveals that ovarian function suppression (OFS) combined with endocrine therapy significantly improves long-term survival in premenopausal women with HER2-positive, hormone receptor-positive breast cancer. • The 10-year disease-free survival rate increased from 59.6% with tamoxifen alone to 70.9% with the addition of OFS, demonstrating a substantial benefit in disease control. • Overall survival rates at 10 years also saw a marked improvement, rising from 74.0% to 84.7% with the inclusion of OFS in the treatment regimen. • While OFS can be challenging due to toxicity, its use should be considered in selected high-risk patients to improve survival outcomes.